Related Experiment Video
Updated: Aug 5, 2026
Establishment of Pancreatic Cancer-Derived Tumor Organoids and Fibroblasts From Fresh Tissue
Published on: May 26, 2023
From patient-derived tumor organoids to personalized cancer therapy: advancing treatment for advanced solid tumors
Gang Wang1, Zhibin Tan2, Wenting Jia1
1Department of Chemoradiation, North China University of Science and Technology Affiliated Hospital, Tangshan, Hebei, China.
Background:
Cancer remains a major global public health burden, with high morbidity and mortality. Despite advances in treatment strategies, many patients with advanced solid tumors face treatment resistance and limited therapeutic options. Patient-derived tumor organoids (PDTOs) have emerged as promising preclinical models for personalized medicine, but their clinical translational potential in guiding individualized treatment for advanced solid tumors requires further validation.
Methods:
The sample data of 164 solid tumors used for establishing organoids were retrospectively analyzed, and a clinical cohort involving 23 patients with advanced solid tumors was used to validate the feasibility of PDTOs in predicting the treatment response. The concordance between PDTO drug responses and clinical outcomes was evaluated using Cohen's Kappa test.
Results:
The overall establishment success rate of organoids reached 91.5%, with the rates ranging from 90.6% to 92.6% across different cancer types. Histopathological analysis confirmed that PDTOs partially recapitulated the histopathological features and proliferative activity of matched original tumors. PDTO-based drug sensitivity testing showed good concordance with clinical treatment outcomes of patients with advanced solid tumors, yielding an overall accuracy of 85.0%, a sensitivity of 86.7%, a specificity of 80.0%. Clinical case studies further highlighted the unique value of PDTOs in overcoming multidrug resistance in advanced solid tumors.
Conclusions:
This study demonstrates that PDTOs exhibit favorable potential for predicting treatment responses in patients with advanced solid tumors, and may serve as a promising auxiliary companion diagnostic tool to inform personalized cancer therapy and assist in evaluating multidrug resistance for advanced solid tumors. Future large-scale, multicenter studies with stratified subgroup validations are warranted to further verify the clinical translational value of PDTOs in individualized tumor treatment.
Insights
Patient-derived tumor organoids (PDTOs) show high success rates in predicting treatment responses for advanced solid tumors. These organoids offer a promising tool for personalized cancer therapy and overcoming multidrug resistance.
Area of Science:
- Oncology
- Translational Medicine
- Cancer Research
Background:
- Cancer poses a significant global health challenge with high morbidity and mortality.
- Advanced solid tumors often exhibit treatment resistance, limiting therapeutic options.
- Patient-derived tumor organoids (PDTOs) are emerging preclinical models for personalized medicine, but require clinical validation for advanced solid tumors.
Purpose of the Study:
- To validate the clinical translational potential of PDTOs in guiding individualized treatment for advanced solid tumors.
- To assess the feasibility of PDTOs in predicting patient treatment response.
- To evaluate the concordance between PDTO drug responses and clinical outcomes.
Main Methods:
- Retrospective analysis of 164 solid tumor samples for organoid establishment.
- Validation using a clinical cohort of 23 patients with advanced solid tumors.
- Evaluation of concordance using Cohen's Kappa test.
Main Results:
- High organoid establishment success rate (91.5%) across various cancer types.
- PDTOs partially recapitulated histopathological features and proliferative activity of original tumors.
- PDTO drug sensitivity testing showed 85.0% accuracy, 86.7% sensitivity, and 80.0% specificity in predicting clinical outcomes.
Conclusions:
- PDTOs demonstrate significant potential in predicting treatment responses for advanced solid tumors.
- PDTOs can serve as a valuable companion diagnostic tool for personalized cancer therapy.
- Further large-scale, multicenter studies are needed to confirm the clinical utility of PDTOs in individualized tumor treatment.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...